Liver Cancer/HCC
Liver Cancer/HCC
Blood Test Could Help Predict Which Hepatitis B Patients Will Develop Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 09 June 2016 00:00
- Written by Thomas Jefferson University
A blood test that measures a set of circulating microRNAs (miRNAs) may help identify who will develop hepatitis B virus-related hepatocellular carcinoma (HCC), a type of primary liver cancer, according to research published in the May 24 online edition of OncoTarget.
Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 15 March 2016 00:00
- Written by Liz Highleyman
Overall cancer rates have declined significantly in the U.S. over the past decade thanks to better screening and prevention, with the notable exception of liver cancer, according to a new Annual Report to the Nation on the Status of Cancer. A majority of liver cancer is caused by hepatitis B virus (HBV), which is preventable with a vaccine, or hepatitis C virus (HCV), which can now be cured in most cases.
ASCO 2015: PD-1 Checkpoint Inhibitor Nivolumab Shows Promise against Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 02 June 2015 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor nivolumab (Opdivo) was a star of the show at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago, with study results showing that the drug demonstrated anti-tumor activity against hepatocellular carcinoma in a Phase 1/2 study, along with further Phase 3 evidence of its effectiveness against lung cancer and melanoma.
Hepatitis B Vaccine, Hepatitis C Treatment Could Prevent Most Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 04 February 2016 00:00
- Written by World Hepatitis Alliance
Widespread vaccination against hepatitis B virus (HBV) and prompt treatment of chronic hepatitis C virus (HCV) -- which together are the most common cause of hepatocellular carcinoma -- could prevent an estimated 80% of liver cancer deaths, according to the World Hepatitis Alliance in an announcement commemorating World Cancer Day.
Everolimus Did Not Improve Survival for Advanced Liver Cancer Patients
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 03 July 2014 00:00
- Written by JAMA
The mTOR inhibitor everolimus (Afinator) failed to increase overall survival for people with advanced hepatocellular carccinoma (HCC) who were previously unsuccessfully treated with sorafenib, according to results from the EVOLVE-1 trial published in the July 2 edition of JAMA.
More Articles...
- Antiviral Treatment for Hepatitis B Lowers Risk of Liver Cancer
- EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment
- ILCA 2013: High HBV Viral Load Raises Risk of Progression to Liver Cancer
- ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV
Web Design and Development by